Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
78

Summary

Conditions
Celiac Disease
Type
Interventional
Phase
Phase 1
Design
Allocation: RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: This is a 3-part study. Parts A and C will have a 5 period crossover design Part B will be conducted as a parallel group dose escalation study.Masking: Double (Participant, Investigator)Masking Description: Parts A and B will be double blind and Part C will be open label.Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 50 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04604795
Collaborators
Not Provided
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline